Investing.com -- Wall Street analysts are divided on the outlook for Burberry (LON:BRBY) following its latest quarterly results and strategy update. UBS upgraded the stock to Buy from Neutral, raising its price target to 1,400p from 918p. The bank cited a more focused strategy aligned with Burberry’s heritage as a key reason for turning positive. Advertisement: High Yield Savings Offers Earn 4.10% APY** on balances of $5,000 or more View Offer Earn up to 4.00% APY with Savings Pods View Offer Earn up to 3.80% APY¹ & up to $300 Cash Bonus with Direct Deposit View Offer Powered by Money.com - Yahoo may earn commission from the links above. UBS analysts said the renewed emphasis on outerwear, heritage styles, and more accessible price points comes at a time when luxury consumers are showing signs of fatigue. “The weakness in the luxury sector due to limited newness and stretched price points, will enable market share gains at lower incremental cost,” analysts led by Zuzanna Pusz, wrote, adding that this shift underpins a projected earnings per share (EPS) compound annual growth rate (CAGR) of 85% through fiscal 2028 (FY28). UBS now sees EBIT margins climbing back to ~16% by FY30, supported by stronger sales forecasts, incremental cost-cutting, and the reduction of outlet exposure. The bank values the stock using a mix of discounted cash flow (DCF) and relative enterprise value (EV)/sales metrics, arguing the turnaround trajectory is underappreciated by the market. “In our view, should the positive EPS momentum continue BRBY shares appear relatively cheap, with 2026 PEG ratio of <1x, far below luxury and sportswear sectors as well as premium apparel peers,” the analysts said. In contrast, Deutsche Bank downgraded Burberry to Hold from Buy, despite acknowledging early signs of brand recovery. The bank raised its target to 1,000p from 900p, but warned that the recovery story has already been largely priced in after a stronger-than-expected FY25 and upbeat management commentary. Analyst Adam Cochrane noted that further upside would require either cFX sales growth in the double digits or EBIT margins to exceed mid-teens guidance by 2028. “This may be feasible but more evidence that the success in the heritage ranges can be carried across the remainder of the range is required, in our view,” he wrote. Related articles Wall Street mixed on Burberry as UBS upgrades, Deutsche Bank downgrades the stock Here are 3 key reasons why markets are rallying Petrobras upgraded to Buy at Jefferies as cost-cutting improves risk-reward View Comments
Wall Street mixed on Burberry as UBS upgrades, Deutsche Bank downgrades the stock
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...